<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178993</url>
  </required_header>
  <id_info>
    <org_study_id>BED(IN):40</org_study_id>
    <secondary_id>R01DA047391</secondary_id>
    <nct_id>NCT04178993</nct_id>
  </id_info>
  <brief_title>Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]</brief_title>
  <official_title>A Novel Drug Combination as a Pharmacotherapeutic for Methamphetamine-Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig Rush</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the behavioral effects of methamphetamine during maintenance on
      placebo, duloxetine, methylphenidate and duloxetine combined with methylphenidate using
      sophisticated human laboratory methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reinforcing Effects of Methamphetamine Following Placebo Maintenance.</measure>
    <time_frame>Following at least 4 days of maintenance on placebo during inpatient admission</time_frame>
    <description>Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reinforcing Effects of Methamphetamine Following Duloxetine Maintenance.</measure>
    <time_frame>Following at least 4 days of maintenance on duloxetine during inpatient admission</time_frame>
    <description>Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reinforcing Effects of Methamphetamine Following Methylphenidate Maintenance.</measure>
    <time_frame>Following at least 4 days of maintenance on methylphenidate during inpatient admission</time_frame>
    <description>Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reinforcing Effects of Methylphenidate Following Methylphenidate and Duloxetine Maintenance</measure>
    <time_frame>Following at least 4 days of maintenance on methylphenidate and duloxetine during inpatient admission.</time_frame>
    <description>Number of methamphetamine doses earned by subjects on a progressive ratio schedule of reinforcement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Effect Questionnaire</measure>
    <time_frame>12 sessions over approximately 4.5 weeks of study participation</time_frame>
    <description>Subjects will complete the drug effect questionnaire during nine sessions while they are admitted to our inpatient unit. The items (total scores=0-100; Higher scores=greater drug effect) on this scale categorize the constellation of drug effects endorsed by subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Daily over approximately 4.5 weeks of inpatient stay.</time_frame>
    <description>Beats per minute. Measured daily during inpatient admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Daily over approximately 4.5 weeks of inpatient stay.</time_frame>
    <description>mmHg.Measured daily during inpatient admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Daily over approximately 4.5 weeks of inpatient stay.</time_frame>
    <description>Degrees fahrenheit. Measured daily during inpatient admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Daily over approximately 4.5 weeks of inpatient stay.</time_frame>
    <description>Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Attentional Bias</measure>
    <time_frame>12 sessions over approximately 4.5 weeks of study participation</time_frame>
    <description>Subjects will complete attentional bias during 12 sessions while they are admitted to our inpatient unit. Time attending to drug stimuli will be used to evaluate attentional bias.</description>
  </other_outcome>
  <other_outcome>
    <measure>Delay Discounting Task</measure>
    <time_frame>12 sessions over approximately 4.5 weeks of study participation</time_frame>
    <description>Subjects will complete the delay discounting task during twelve sessions while they are admitted to our inpatient unit. Responses will be used to calculate discounting slope (i.e., K).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anhedonia (Inability to experience pleasure)</measure>
    <time_frame>12 sessions over approximately 4.5 weeks of study participation</time_frame>
    <description>A 14-item pleasure scale covers four domains of pleasure response: interest/pastimes, social interaction, sensory experience and food/drink.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Methamphetamine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methamphetamine</intervention_name>
    <description>In each arm, subjects will receive doses of methamphetamine.</description>
    <arm_group_label>Active Comparator: Duloxetine</arm_group_label>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Metamfetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>In each arm, subjects will receive methylphenidate capsules.</description>
    <arm_group_label>Active Comparator: Duloxetine</arm_group_label>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Metadate®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>In each arm, subjects will receive placebo capsules.</description>
    <arm_group_label>Active Comparator: Duloxetine</arm_group_label>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Subjects will receive duloxetine capsules in the duloxetine arm.</description>
    <arm_group_label>Active Comparator: Duloxetine</arm_group_label>
    <other_name>Cymbalta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recent use of inhaled (i.e., snorted), smoked or injected methamphetamine

        Exclusion Criteria:

          -  Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians
             deem clinically significant.

          -  Current or past histories of substance use that are deemed by the study physicians to
             interfere with study completion.

          -  History of serious physical disease, current physical disease, impaired cardiovascular
             functioning, chronic obstructive pulmonary disease, history of seizure or current or
             past histories of serious psychiatric disorder that in the opinion of the study
             physician would interfere with study participation will be excluded from
             participation.

          -  Females not currently using effective birth control.

          -  Contraindications to methamphetamine, methylphenidate, or duloxetine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frances Wagner, RN</last_name>
    <phone>(859) 257-5388</phone>
    <email>fpwagn2@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wagner Frances, RN</last_name>
      <phone>859-257-5388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig R Rush, Ph.D.</last_name>
      <phone>859-257-5388</phone>
      <email>crush2@email.uky.edu</email>
    </contact>
    <investigator>
      <last_name>Craig R Rush, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Craig Rush</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Duloxetine Hydrochloride</keyword>
  <keyword>Central Nervous System Stimulants</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Dopamine Uptake Inhibitors</keyword>
  <keyword>Serotonin and Noradrenaline Reuptake Inhibitors</keyword>
  <keyword>Membrane Transport Modulators</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Dopamine Agents</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Sensory System Agents</keyword>
  <keyword>Peripheral Nervous System Agents</keyword>
  <keyword>Vasoconstrictor Agents</keyword>
  <keyword>Antidepressive Agents</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

